Coverage stance: covered_with_criteria for the FDA-approved indication of Onapgo (apomorphine subcutaneous infusion) for motor fluctuations in adults with advanced Parkinson's disease. Scope summary: Cigna coverage policy addressing prior authorization, required clinical criteria for approval, dosing limits, contraindications, and coding for members of Cigna-administered health benefit plans. FDA-approved indication summary: Onapgo is indicated for the treatment of motor fluctuations in adults with advanced Parkinson's disease. High-level approval conditions: approvals require prior authorization and are approved for 1 year if all clinical criteria are met; initial prescriptions must be by or in consultation with a neurologist/specialist. Dosing limits: approve up to 98 mg administered as a subcutaneous infusion every day.